Filing Details
- Accession Number:
- 0000899243-20-031115
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-11-16 16:05:14
- Reporting Period:
- 2020-11-12
- Accepted Time:
- 2020-11-16 16:05:14
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1274792 | Merrimack Pharmaceuticals Inc | MACK | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1548707 | Newtyn Partners, Lp | 60 East 42Nd Street, 9Th Floor New York NY 10165 | No | No | No | Yes | |
1548709 | Newtyn Te Partners, Lp | 60 East 42Nd Street, 9Th Floor New York NY 10165 | No | No | No | Yes | |
1569241 | Newtyn Management, Llc | 60 East 42Nd Street, 9Th Floor New York NY 10165 | No | No | No | Yes | |
1788608 | G. Noah Levy | 60 East 42Nd Street, 9Th Floor New York NY 10165 | Yes | No | No | Yes | |
1789643 | Newtyn Capital Partners, Lp | 60 East 42Nd Street, 9Th Floor New York NY 10165 | No | No | No | Yes | |
1789647 | Ledo Capital, Llc | 60 East 42Nd Street, 9Th Floor New York NY 10165 | No | No | No | Yes |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-11-12 | 32,934 | $3.65 | 839,005 | No | 4 | P | Indirect | See footnote |
Common Stock | Acquisiton | 2020-11-12 | 23,556 | $3.65 | 611,015 | No | 4 | P | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.60 to $3.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.60 to $3.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.